Literature DB >> 8561147

Prevalence of oral lesions in inflammatory bowel disease.

D Lisciandrano1, T Ranzi, A Carrassi, A Sardella, M C Campanini, P Velio, P A Bianchi.   

Abstract

OBJECTIVE: To obtain precise data on the prevalence of oral lesions in inflammatory bowel disease (IBD).
METHODS: Oral lesions were carefully sought in a consecutive series of 198 Italian IBD outpatients, 77 with Crohn's disease (CD) and 121 with ulcerative colitis (UC); 89 subjects with functional intestinal motility disorders served as controls.
RESULTS: The oral lesions detected were angular cheilitis (in 7.8% of CD patients, 5% of UC patients, and 0% of controls (p < 0.05, patients vs controls), lichen (6.5, 5.8, and 3.3%, respectively, p = not significant), aphthous ulcers (5.2, 5.8, and 5.6%, respectively, p = not significant), candidiasis (5.2, 0.8, and 0%, respectively, p < 0.05, CD patients vs controls), benign tumors (5.2, 0, and 7.8%, respectively, p < 0.05, patients vs controls), leukoplakia (5.2, 11, and 3.3%, respectively, p = not significant), and, less frequently, glossitis and herpes labialis. No specific CD oral lesions were observed in this series. No correlation was found between clinical disease activity and frequency of oral lesions.
CONCLUSIONS: Aphthous ulcers are not common in IBD patients. Oral candidiasis is more frequent in CD than UC patients and controls.

Entities:  

Mesh:

Year:  1996        PMID: 8561147

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  10 in total

Review 1.  Gastrointestinal diseases and their oro-dental manifestations: Part 2: Ulcerative colitis.

Authors:  C X W Tan; H S Brand; N K H de Boer; T Forouzanfar
Journal:  Br Dent J       Date:  2017-01-13       Impact factor: 1.626

Review 2.  Important cutaneous manifestations of inflammatory bowel disease.

Authors:  L B Trost; J K McDonnell
Journal:  Postgrad Med J       Date:  2005-09       Impact factor: 2.401

Review 3.  Pulmonary involvement and allergic disorders in inflammatory bowel disease.

Authors:  Nikolaos E Tzanakis; Ioanna G Tsiligianni; Nikolaos M Siafakas
Journal:  World J Gastroenterol       Date:  2010-01-21       Impact factor: 5.742

4.  Amlexanox for the treatment of recurrent aphthous ulcers.

Authors:  Juliette Bell
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

Review 5.  Oral manifestation in inflammatory bowel disease: a review.

Authors:  Kamran B Lankarani; Gholam Reza Sivandzadeh; Shima Hassanpour
Journal:  World J Gastroenterol       Date:  2013-12-14       Impact factor: 5.742

Review 6.  Oral manifestations of gastrointestinal disorders.

Authors:  Martin Jajam; Patricia Bozzolo; Sven Niklander
Journal:  J Clin Exp Dent       Date:  2017-10-01

7.  The Association between Periodontitis and Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.

Authors:  Yangheng Zhang; Dan Qiao; Rixin Chen; Feng Zhu; Jianfeng Gong; Fuhua Yan
Journal:  Biomed Res Int       Date:  2021-03-12       Impact factor: 3.411

8.  A potential pathogenic association between periodontal disease and Crohn's disease.

Authors:  Jin Imai; Hitoshi Ichikawa; Sho Kitamoto; Jonathan L Golob; Motoki Kaneko; Junko Nagata; Miho Takahashi; Merritt G Gillilland; Rika Tanaka; Hiroko Nagao-Kitamoto; Atsushi Hayashi; Kohei Sugihara; Shrinivas Bishu; Shingo Tsuda; Hiroyuki Ito; Seiichiro Kojima; Kazunari Karakida; Masashi Matsushima; Takayoshi Suzuki; Katsuto Hozumi; Norihito Watanabe; William V Giannobile; Takayuki Shirai; Hidekazu Suzuki; Nobuhiko Kamada
Journal:  JCI Insight       Date:  2021-12-08

9.  Childhood onset of Crohn disease: experience from a university teaching hospital in Saudi Arabia.

Authors:  Omar I Saadah
Journal:  Ann Saudi Med       Date:  2012 Nov-Dec       Impact factor: 1.526

10.  Oral health and salivary function in ulcerative colitis patients.

Authors:  Ariana Goldinova; Christopher Xw Tan; Gerd Bouma; Marjolijn Duijvestein; Henk S Brand; Nanne K de Boer
Journal:  United European Gastroenterol J       Date:  2020-09-02       Impact factor: 4.623

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.